Rs7911488 modified the efficacy of capecitabine-based therapy in colon cancer through altering miR-1307-3p and TYMS expression

Capecitabine is an orally administered prodrug of 5-fluouracil (5-FU) and is used in first-line treatment of metastatic colorectal cancer. Studies have demonstrated that polymorphisms in 5-FU related ADME genes are associated with the efficacy of capecitabine. However, the relationship between the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Qi, Mao, Yong, Meng, Fanyi, Wang, Lei, Zhang, Hongjian, Wang, Weipeng, Hua, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650342/
https://www.ncbi.nlm.nih.gov/pubmed/29088787
http://dx.doi.org/10.18632/oncotarget.19670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650342/
https://www.ncbi.nlm.nih.gov/pubmed/29088787
http://dx.doi.org/10.18632/oncotarget.19670

Ejemplares similares